Form 8-K Aurinia Pharmaceuticals For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Leerink Partners Reiterates Outperform Rating on Aurinia Pharmaceuticals (AUPH)
June 30, 2025 1:10 PM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $10.00 price target on Aurinia Pharmaceuticals (NASDAQ: AUPH).
The analyst comments "First-in-human (FIH) data with aritinercept (AUR200) appear competitive with the many other APRIL/ BAFF assets in development; however, we await the initiation of clinical studies in autoimmune diseases in 2H25 for a better understanding of its potential place in the treatment class. This morning, Aurinia (AUPH, OP) disclosed Ph.1 single ascending dose... More
